The Scotland-based firm said that it will use the money for the development of its cancer tests and commercialization in new markets.

Last week, readers were most interested in a story about two Medicare administrative contractors delaying the implementation of a policy not to cover certain genetic tests.

Of the 30 companies included, 19 companies saw their stock price increase, eight firms saw their share price decrease, and three companies remained essentially flat.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

In one, a North Carolina lab allegedly billed for unnecessary urine drug tests, and in the other a Californian women submitted fraudulent claims for respiratory pathogen testing.

AlterDiag will take full responsibility for the industrialization, regulatory restrictions, and commercialization of the tests.

The firm reported that its full-year 2024 revenues were up slightly as a rise in the diagnostics business was mostly offset by a decline in life sciences business.

The small Baltimore-based lab is preparing for the possibility of additional appeals as years of litigation wind down.

Quest said that while it will continue to look at acquisition opportunities, it plans to focus on integrating and driving productivity of recently purchased assets.

NEW YORK – In March, a new EU-funded project will commence that aims to deliver a series of new tests and tools for diagnosing urinary tract infections in low- and medium-income countries, especially ...